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VIRAL EXPRESSION OF TSG-6 CAN STIMULATE OSTEOPHYTE
FORMATION IN EXPERIMENTAL OSTEOARTHRITIS
M.G. Broeren, M.B. Bennink, O.J. Arntz, A.B. Blom, W.B. van den Berg,
F.A. van de Loo. Radboud Univ. Med. center, Nijmegen, Netherlands
Purpose: Tumor necrosis factor-inducible gene 6 (TSG-6, also named
TNFAPI6) is upregulated during experimental arthritis in mice (Geurts
et al. 2009). The therapeutic efﬁcacy of TSG-6 has been shown in
multiple animal models for rheumatoid arthritis, reducing bothinﬂammation and cartilage damage. Recent studies suggest that
inﬂammation can also play a role in early osteoarthritis (OA) patho-
genesis (Ayral et al. 2005). Therefore, TSG-6 therapy might also be an
effective treatment in inﬂammatory OA. In this study, we analyzed the
expression of TSG-6 during experimental arthritis and explored the
effects of TSG-6 gene therapy in a murine model of inﬂammatory
osteoarthritis.
Methods: TSG-6 gene expression was determined in microarrays of
collagenase-induced osteoarthritis at day 7 and day 14 after induction.
The murine TSG-6 genewas cloned in a lentiviral and adenoviral vector.
Freshly isolated bone marrow-derived dendritic cells (BMDCs) were
transduced with the lentiviral vector and subsequently differentiated
into osteoclasts on bone slices with M-CSF and RANKL. After 10 days,
bone slices were washed and stained using Coomassie Blue and bone
resorption was determined using the Leica Application Suite software.
To study the effects of TSG-6 in experimental knee osteoarthritis, mice
received two intra-articular injections of collagenase. Four days prior to
and 20 days after arthritis induction, mice were injected intra-articu-
larly with TSG-6 adenovirus. At day 7, inﬂammation was assessed using
ﬂuorescent Prosense probes. At day 42, knee joints were analyzed by X-
ray and histological assessment.
Results: TSG-6 was upregulated in collagenase-induced OA (2,6x at day
7 (P<0.05) and 2.5x at day 14 (P¼0.55)). BMDCs transduced with TSG-6
lentivirus showed strong expression of TSG-6. Bone resorption by
BMDC-derived osteoclasts was signiﬁcantly reduced (20.1% surface
erosion with control virus to 10.4%, p¼0.01), providing a possible
mechanism for the therapeutic effects in rheumatoid arthritis models.
At day 7 of collagenase-induced osteoarthritis, no difference in
inﬂammation was detected using the Prosense probes. At day 42, no
improvement on cartilage damage was seen, but X-ray analysis showed
strong osteophyte formation at the femur/tibia region in the knee joint.
Histological analysis showed that the osteophytes contained both bone
and cartilage.
Conclusions: Viral expression of TSG-6 can reduce the bone resorption
activity by BMDC-derived osteoclasts. The expression of TSG-6 by
synovial cells during experimental osteoarthritis results in the for-
mation of osteophytes. These results imply a causative role for TSG-6 in
osteophyte formation, supporting the recent ﬁnding that TSG-6 activity
is associated with radiographic progression of OA (Wisniewski et al.
2014).
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INTRA-ARTICULAR HYALURONIC ACID DELAYS TOTAL KNEE
REPLACEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS:
EVIDENCE FROM A LARGE U.S. HEALTH CLAIMS DATABASE
R. Altman y, S. Lim z, R. Steen x, V. Dasa k. yUCLA, Agua Dulce, CA, USA;
z Seikagaku, Tokyo, Japan; xBioventus Global, Durham, NC, USA;
k Louisiana State Univ., New Orleans, USA
Purpose: To evaluate the impact of one or more courses of treatment
with intraarticular (IA) hyaluronate (HA) compared to no IA HA injec-
tions on the time to total knee replacement (TKR) on patients with
osteoarthritis (OA), using a large administrative claims database.
Methods: Retrospective analysis used the IMS PharMetrics Plus claims
database of approximately 79 million patients to identify patients with
OA of the knee who received TKR within a 6 year selection window
(2007-2013). The initial OA diagnosis in the databasewas the index date
and included patients with knee OA who had continuous enrollment
fromOA diagnosis until TKR. Kaplan-Meier survival analysis was used to
measure time-to-TKR. Subsets were deﬁned by the number of courses
of treatment received, ranging from 0 (no IA HA), 1, 2, 3, 4, to 5 HA
courses. Median timewas the time (in years) at which 50% of patients in
a cohort had received TKR. Log-rank tests were used to compare dif-
ferent cohorts.
Results: The database included 182,022 patients with knee OA and TKR.
Of these, 131,673 (72.3%) patients had no HA, and 50,349 (27.7%)
received at least one course of IA HA. Age, sex, and Charlson comor-
bidity scores were similar among subsets. Of those receiving IA HA, a
total of 36,861 patients (73.2%) received 1 HA course, 8893 (17.7%)
received 2 courses, 2,783 (5.5%) received 3 courses, 1052 (2.1%) received
